References
- Abou-Setta AM, Mousavi SS, Spooner C, et al. AHRQ comparative effectiveness reviews. First-generation versus second-generation antipsychotics in adults: comparative effectiveness. Rockville, MD: Agency for Healthcare Research and Quality (US), 2012
- Jann MW. Diagnosis and treatment of bipolar disorders in adults: a review of the evidence on pharmacologic treatments. Am Health Drug Benefits 2014;7:489-99
- Chitnis A, Wang R, Sun SX, et al. Impact of initiation of asenapine on patterns of utilization and cost of healthcare resources associated with the treatment of bipolar I disorder. doi: 10.3111/13696998.2015.1067221
- Bongards EN, Zaman R, Agius M. Can we prevent under-diagnosis and misdiagnosis of bipolar affective disorder? Repeat audits to assess the epidemiological change in the caseload of a community mental health team when bipolar disorder is accurately assessed and diagnosed. Psychiatr Danub 2013;25(2 Suppl):S129-34
- Amihaesei IC. Bipolar disorder, not so rare diagnosis: subtypes of different degrees of severity, diagnosis, therapy. Rev Med Chir Soc Med Nat Iasi 2014;118:111-15
- Godman B, Petzold M, Bennett K, et al. Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources?: Findings from across Europe and their implications. BMC Med 2014;12:98
- Malmstrom RE, Godman BB, Diogene E, et al. Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol 2013;4:39
- Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159(4 Suppl):1-50
- Vieta E, Gunther O, Locklear J, et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol Official Sci J CINP 2011;14:1029-49
- Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013;15:1-44
- Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-62
- Selle V, Schalkwijk S, Vazquez GH, et al. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry 2014;47:43-52
- Singh AB, Nierenberg AA, Yatham LN, et al. Atypical antipsychotic agents; Peas in a pod or chalk and cheese? BMC Med 2014;12:126
- Cerullo MA, Strakowski SM. A systematic review of the evidence for the treatment of acute depression in bipolar I disorder. CNS Spectrums 2013;18:199-208
- Vita A, De Peri L, Siracusano A, et al. Efficacy and tolerability of asenapine for acute mania in bipolar I disorder: meta-analyses of randomized-controlled trials. Int Clin Psychopharmacol 2013;28:219-27
- Kemp DE, Zhao J, Cazorla P, et al. Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder. J Clin Psychiatry 2014;75:238-45
- Sawyer L, Azorin JM, Chang S, et al. Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes. J Med Econ 2014;17:508-19
- Parks J, Radke A, Parker G, et al. Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. Schizophr Bull 2009;35:931-6
- Godman B, De Bruyn K, Miranda J, et al. Generic atypical antipsychotic drugs in Belgium: their influence and implications. J Comp Eff Res 2013;2:551-61
- Chue P, Chue J. The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia. Exp Rev Pharmacoecon Outcomes Res 2012;12:259-69